Nabta Health has closed a $2 million Pre-Series A round, taking the company’s total funding to US$4.5 million. The women’s health startup said the new capital will support the expansion of its AI-driven hybrid care model across the Middle East and Africa.
According to the company, the funding will be channelled into strengthening partnerships with employers, insurers and healthcare providers, as well as developing additional diagnostic and at-home testing options. Nabta also intends to upgrade its clinical infrastructure through work with leading hospitals in the region.
The announcement follows a year of notable milestones for the company. Nabta launched a Women’s Health Centre of Excellence with Clemenceau Medical Center Hospital Dubai, and extended its corporate health services across MEA. Collectively, the company says these developments highlight its position as an emerging hub for women’s health innovation, built around a model that combines virtual care, in-person services and community-based support.
Sophie Smith, Founder and CEO of Nabta Health, said: “We are delighted to have closed this Pre-Series A round and to bring our total funding to date to US$4.5 million. This investment validates our vision – that women’s health in the region can be reimagined through an AI-powered, hybrid care model that meets women where they are, respects cultural context and delivers measurable outcomes. We are now looking to accelerate our growth so that more women and employers benefit from what we believe is the future of women-centred health: affordable, mobile-first, and engineered for sovereignty.”
“For employers and insurers in the region, addressing the women’s health gap is not just a moral imperative; it is a business and productivity one,” added Smith. “With this funding, we will drive scale, deepen impact and prepare for the next chapter of growth.”
Iain McMillan, Chair of Nabta Health, said: “The closing of this Pre-Series A round is confirmation that Nabta Health is being increasingly recognised in the region as a key enabler of measurably better women’s health. The business has steadily gained traction and grown its customer base throughout 2025 and I am looking forward to seeing further acceleration in our success as we move forward into 2026 and beyond.”
